NasdaqGM:ZLABBiotechs
Is Zai Lab (ZLAB) Quietly Reframing Its Moat Around Differentiated DLL3 and Atopic Pipelines?
Zai Lab recently reported past preclinical and early clinical updates, including new data on its IL-13/IL-31Ra bispecific antibody ZL-1503 for atopic diseases and promising intracranial response data for its DLL3-targeting ADC zocilurtatug pelitecan (zoci) in small cell lung cancer and other neuroendocrine carcinomas.
These developments, alongside a new collaboration with Boehringer Ingelheim on dual DLL3-targeting regimens, underscore Zai Lab’s push into differentiated therapies for...